ASX ANNOUNCEMENT

9 November 2026

Vectus appoints Professor Tamera Corte as Chief Clinical Advisor

HIGHLIGHTS

- Professor Tamera Corte appointed as Chief Clinical Advisor, bringing extensive expertise in pulmonary fibrosis and clinical trial development.
- Professor Corte is Director of Interstitial Lung Disease at Royal Prince Alfred Hospital, Chief Investigator of the Centre of Research Excellence in Pulmonary Fibrosis and Clinical Professor at the University of Sydney.
- Appointment strengthens clinical expertise as Vectus progresses its lead candidate, VB0004, towards an adaptive Phase Ib / IIa trial in idiopathic pulmonary fibrosis (IPF).

Vectus Biosystems Limited (ASX: VBS) (Vectus or the Company) is pleased to announce the appointment of Professor Tamera Corte as its Chief Clinical Advisor.

Professor Corte is a respiratory physician and clinical researcher with extensive experience in interstitial lung disease (ILD), including IPF, the initial target indication for Vectus' lead antifibrotic candidate, VB0004. Her appointment strengthens the Company's clinical capabilities as it advances the programme towards human trials.

Professor Corte is Director of Interstitial Lung Disease at Royal Prince Alfred Hospital and Clinical Professor at the University of Sydney. She is a lead investigator of the Centre of Research Excellence in Pulmonary Fibrosis, Chair of the Australasian Interstitial Lung Disease Registry, and a member of national and international committees involved in ILD clinical trials and treatment guidelines.

Professor Corte co-established the Pulmonary Fibrosis Australasian Clinical Trials Network and has served as a principal investigator in more than 40 commercially-sponsored ILD clinical trials. Her experience includes participation in global clinical trial steering committees, and leadership of a pulmonary fibrosis clinical and translational research programme.

In her role as Chief Clinical Advisor, Professor Corte will provide clinical and strategic advice on Vectus' development programmes, with an initial focus on VB0004 in IPF. Her proposed responsibilities include advising on clinical trial design, patient selection, clinically relevant endpoints and engagement with investigators.

The Company's Chief Executive Officer and Chief Technology Officer (CEO & CTO), Dr Tara Speranza, commented:

"We're thrilled to have someone of Tamera's calibre to provide key clinical, medical and strategic advice to us at Vectus. Her experience in treating patients with pulmonary fibrosis and evaluating investigational therapies will be particularly valuable as we prepare for the next stage of VB0004's clinical development.

"Tamera brings a practical understanding of the challenges facing patients and clinicians, alongside extensive experience in international clinical trials. Her input will help us design a programme that can meaningfully assess VB0004's potential in IPF and guide our clinical development priorities."

The appointment supports the Company's preparations for a planned adaptive Phase Ib / IIa clinical trial of VB0004 in IPF. VB0004 is a small-molecule vasoactive intestinal peptide mimetic and natriuretic peptide receptor C agonist. Vectus has completed Phase Ia studies, with a pharmacokinetic profile consistent with once-daily oral dosing.

The Company is also progressing the US regulatory pathway for VB0004. As announced on 30 September 2026, the US Food and Drug Administration granted Vectus' request for a pre-Investigational New Drug Type B meeting, with written responses on the proposed IPF development programme expected by mid-November 2026. This feedback is expected to inform the Company's next clinical and regulatory steps.

Professor Corte commented:

"There remains a substantial need for additional treatment options for people living with pulmonary fibrosis. Developing new therapies requires carefully designed clinical studies that address both the underlying disease and outcomes that matter to patients.

"I look forward to working with the Vectus team as it progresses VB0004 towards clinical evaluation in people with IPF."

Ronald Shnier
Chairman

Tara Speranza
CEO & CTO
info@vectusbiosystems.com.au

This announcement was authorised by the Board of Directors

About Vectus Biosystems Limited

Vectus Biosystems Limited (ASX:VBS) is an Australian clinical-stage biotechnology company developing novel therapies for fibrotic diseases, with an initial focus on advancing its lead compound, VB0004, for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, and often fatal, lung disease with significant unmet medical need. VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models, and has successfully completed Phase Ia clinical studies, establishing a favourable safety and pharmacokinetic profile.

Beyond IPF, the Company is advancing a broader pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis, leveraging a platform approach to address diseases driven by pathological tissue scarring. The commercial potential of the platform has been externally validated through a licensing agreement with an international biotechnology company for one of Vectus' renal fibrosis assets, showing a pathway for potential future milestone and royalty revenues.

The Company will continue its clinical development with an ambition to create shareholder value through the advancement, partnering and commercialisation of innovative therapies that address significant unmet needs in fibrotic disease.